£595.00

The 2016-2021 Outlook for Multiple Sclerosis Therapeutics in the United States

Econometrics

Price data last checked 20 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£595 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 71 days · 71 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 71 days • 1 price levels

Days at Price

Price Analysis

Most common price: £595 (71 days, 100.0%)

Price range: £595 - £595

Price levels: 1 different prices over 71 days

Description

This econometric study covers the latent demand outlook for Multiple Sclerosis therapeutics across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,700 cities in the United States. For each city in question, the percent share the city is of it's state and of the United States is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-a-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for Multiple Sclerosis therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the cities in the United States). This study gives, however, my estimates for the latent demand, or the P.I.E., for Multiple Sclerosis therapeutics in the United States. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of the United States. For each state, I also show my estimates of how the P.I.E. grows over time. In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on strategic planning at graduate schools of business.

Product Specifications

Format: paperback
ASIN: B01GEP5JBO
Category: Books > Subjects > Business, Finance & Law > Economics > Econometrics
Domain: Amazon UK
Release Date: 30 September 2015
Listed Since: 31 May 2016

The 2016-2021 Outlook for Multiple Sclerosis Therapeutics in the United States

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2016 Report on Multiple Sclerosis Therapeutics: World Market Segmentation by City

The 2023 Report on Multiple Sclerosis Therapeutics: World Market Segmentation by City

The 2023-2028 Outlook for Beta Interferon Therapeutics for Multiple Sclerosis in the United States

The 2023 Report on Multiple Sclerosis Treatments: World Market Segmentation by City

The 2023-2028 Outlook for Beta Interferon Therapeutics for Multiple Sclerosis in India

The 2016-2021 Outlook for Management, Consulting, and Public Relations Services in the United States

The 2016-2021 Outlook for Media Sales Representatives in the United States

The 2016-2021 Outlook for Enterprise Mashup Applications and Platforms in the United States

The 2025-2030 World Outlook for Beta Interferon Therapeutics for Multiple Sclerosis

The 2023-2028 Outlook for Advanced Therapy Medicinal Products in the United States

The 2016-2021 Outlook for Online Social Interaction Services in the United States

The 2016-2021 Outlook for Non-Electronic Games in the United States

The 2016-2021 Outlook for Video Games Software in the United States

The 2016-2021 Outlook for Pharmaceutical Preparations for Human Use Acting on the Central Nervous System and the Sense Organs in the United States

The 2016-2021 Outlook for Non-Food Retail Sales in the United States

The 2016-2021 Outlook for Next-Generation Mobile Software in Japan

The 2016-2021 Outlook for Pharmaceutical Preparations Affecting the Central Nervous System and Sense Organs in the United States

The 2016-2021 Outlook for Non-Small Cell Lung Cancer Therapeutics in the United States

Living with Multiple Sclerosis: A Group-Based Psychological Support Intervention for Newly Diagnosed People with MS (LiMS)

The 2023-2028 Outlook for Mobile Medical Apps in the United States

The 2016-2021 Outlook for Information Technology (IT) Services and Outsourcing Services in the United States

The 2016-2021 Outlook for Media Sales Representatives in Greater China

The 2016-2021 Outlook for Interior Design Services in the United States

Multiple Sclerosis in Children and Adolescents - Medical Book